AHSP (alpha hemoglobin stabilizing protein) is a specialized molecular chaperone that prevents harmful aggregation of free alpha-hemoglobin during erythroid development. AHSP functions as a scavenger protein by reversibly binding to excess alpha-globin chains, forming a stable AHSP-αHb complex that protects against precipitation 1. This mechanism is critical because higher AHSP gene dosage leads to approximately twice as much alpha subunit production relative to beta subunit, creating excess free alpha-hemoglobin prone to aggregation 1. AHSP plays a significant modulatory role in beta-thalassemia, where deficient beta-globin production results in dangerous alpha-globin accumulation. AHSP gene mutations are associated with disease severity variation in HbE beta-thalassemia patients; exon 3 mutations particularly correlate with transfusion-dependent thalassemia phenotypes 2. AHSP gene expression increases with clinical disease severity, suggesting a compensatory response to excess alpha-hemoglobin burden 3. As one of a rare class of "faithful chaperones" that assist only single target proteins, AHSP's high-level production is evolutionarily maintained despite metabolic costs, reflecting the essential nature of alpha-hemoglobin folding 4. AHSP represents a potential therapeutic target for modulating beta-thalassemia severity and managing alpha-globin excess disorders.